Prasinezumab + Placebo
Phase 2Active 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Parkinsons Disease
Conditions
Parkinsons Disease
Trial Timeline
May 5, 2021 → Dec 30, 2026
NCT ID
NCT04777331About Prasinezumab + Placebo
Prasinezumab + Placebo is a phase 2 stage product being developed by Roche for Parkinsons Disease. The current trial status is active. This product is registered under clinical trial identifier NCT04777331. Target conditions include Parkinsons Disease.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07174310 | Phase 3 | Recruiting |
| NCT04777331 | Phase 2 | Active |
Competing Products
5 competing products in Parkinsons Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Mirabegron + Placebo | Astellas Pharma | Approved | 85 |
| Rivastigmine Patch 9.5 cm2 | Novartis | Approved | 85 |
| ALN-SNCA + Placebo | Regeneron Pharmaceuticals | Phase 1 | 32 |
| bemdaneprocel | Bayer | Phase 3 | 74 |
| High dose ANAVEX2-73 + Mid dose ANAVEX2-73 + Placebo oral capsule | Anavex Life Sciences | Phase 2 | 44 |